TY - JOUR
T1 - Growth patterns of uninfected children born to women living with perinatally versus nonperinatally acquired HIV
AU - the Pediatric HIV/AIDS Cohort Study (PHACS)
AU - Yu, Wendy
AU - Jacobson, Denise L.
AU - Williams, Paige L.
AU - Patel, Kunjal
AU - Geffner, Mitchell E.
AU - van Dyke, Russell B.
AU - Kacanek, Deborah
AU - DiMeglio, Linda A.
AU - Jao, Jennifer
AU - Chadwick, Ellen
AU - Sanders, Margaret Ann
AU - Malee, Kathleen
AU - Paul, Mary
AU - Eser-Jose, Ruth
AU - McMullen-Jackson, Chivon
AU - Harris, Lynnette
AU - Purswani, Murli
AU - Baig, Mahoobullah Mirza
AU - Villegas, Alma
AU - Alvarado, Marvin
AU - Robinson, Lisa Gaye
AU - Cooley, Jawara Dia
AU - Blood, James
AU - Garvie, Patricia
AU - Borkowsky, William
AU - Deygoo, Nagamah Sandra
AU - Lewis, Jennifer
AU - Dieudonne, Arry
AU - Bettica, Linda
AU - Johnson, Juliette
AU - Surowiec, Karen
AU - Knapp, Katherine
AU - Russell-Bell, Jamie
AU - Wilkins, Megan
AU - Love, Stephanie
AU - Rosario, Nicolas
AU - Angeli-Nieves, Lourdes
AU - Olivera, Vivian
AU - Kohlhoff, Stephan
AU - Dennie, Ava
AU - Kaye, Jean
AU - Wallier, Jenny
AU - Craig, Karen
AU - Sirois, Patricia
AU - Hutto, Cecelia
AU - Hickman, Paige
AU - Huldtquist, Julie
AU - Marullo, Dan
AU - Spector, Stephen A.
AU - Figueroa, Veronica
N1 - Funding Information:
The study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Office of The Director, National Institutes of Health (OD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), and National Institute on Alcohol Abuse and Alcoholism (NIAAA) through cooperative agreements with the Harvard T.H. Chan School of Public Health (HD052102) (Principal Investigator: George R Seage III; Program Director: Liz Salomon) and the Tulane University School of Medicine (HD052104) (Principal Investigator: Russell Van Dyke; Co-Principal Investigator: Ellen Chadwick; Project Director: Patrick Davis), and through P01HD103133 with Harvard T.H. Chan School of Public Health for the Pediatric HIV/AIDS Cohort Study (PHACS) 2020 (Multiple Principal Investigators: George R Seage III, Ellen Chadwick; Program Director: Liz Salomon). Data management services were provided by Frontier Science (Data Management Center Director: Suzanne Siminski), and regulatory services and logistical support were provided by Westat, Inc (Project Directors: Julie Davidson, Tracy Wolbach).
Funding Information:
The study was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), Office of The Director, National Institutes of Health (OD), National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Neurological Disorders and Stroke (NINDS), National Institute on Deafness and Other Communication Disorders (NIDCD), National Institute of Mental Health (NIMH), National Institute on Drug Abuse (NIDA), National Cancer Institute (NCI), and National Institute on Alcohol Abuse and Alcoholism (NIAAA) through cooperative agreements with the Harvard T.H. Chan School of Public Health (HD052102) (Principal Investigator: George R Seage III; Program Director: Liz Salomon) and the Tulane University School of Medicine (HD052104) (Principal Investigator: Russell Van Dyke; Co-Principal Investigator: Ellen Chadwick; Project Director: Patrick Davis), and through P01HD103133 with Harvard T.H. Chan School of Public Health for the Pediatric HIV/AIDS Cohort Study (PHACS) 2020 (Multiple Principal Investigators: George R Seage III, Ellen Chadwick; Program Director: Liz Salomon). Data management services were provided by Frontier Science (Data Management Center Director: Suzanne Siminski), and regulatory services and logistical support were provided by Westat, Inc (Project Directors: Julie Davidson, Tracy Wolbach).
Publisher Copyright:
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2022/3/15
Y1 - 2022/3/15
N2 - Objective: The aim of this study was to compare long-term growth between HIV-exposed uninfected children (CHEU) born to women with perinatally acquired HIV (CHEU-PHIV) and CHEU born to women with nonperinatally acquired HIV (CHEU-NPHIV). Design: A longitudinal analysis of anthropometric measurements from a U.S.-based multisite prospective cohort study enrolling CHEU and their mothers since April 2007. Methods: CHEU were evaluated for growth annually from birth through age 5 and again at age 7 years. Z-scores were calculated using U.S. growth references for weight (WTZ), height (HTZ), and weight-for-length or BMI-for-age (WLZ/BMIZ). Mid-upper arm circumference (MUACZ) and triceps skinfold thickness (TSFZ) Z-scores were obtained from ages 1 and 2, respectively, through age 7 years. Piecewise mixed-effects models, overall and stratified by race and sex, were fit to assess differential growth patterns across age by maternal PHIV status. Results: One thousand four hundred fifty-four singleton infants (286 CHEU-PHIV and 1168 CHEU-NPHIV) were included. CHEU-PHIV had slower growth rates than CHEU-NPHIV for WTZ and WLZ/BMIZ at earlier ages and continued to have lower mean WTZ [-0.27, 95% confidence interval (95% CI): -0.50, -0.04] and WLZ/BMIZ (-0.39, 95% CI: -0.67, -0.11) through age 7. Among non-Black boys, CHEU-PHIV had slightly lower WTZ and WLZ/BMIZ at birth than CHEU-NPHIV and these growth deficits persisted through age 7 years. Conclusion: Compared with CHEU-NPHIV, CHEU-PHIV had diminished growth in early childhood with differences most pronounced among non-Black male children. Further longitudinal follow-up of CHEU-PHIV into young adulthood is needed to understand whether these early effects of maternal PHIV status on growth persist and have other health consequences.
AB - Objective: The aim of this study was to compare long-term growth between HIV-exposed uninfected children (CHEU) born to women with perinatally acquired HIV (CHEU-PHIV) and CHEU born to women with nonperinatally acquired HIV (CHEU-NPHIV). Design: A longitudinal analysis of anthropometric measurements from a U.S.-based multisite prospective cohort study enrolling CHEU and their mothers since April 2007. Methods: CHEU were evaluated for growth annually from birth through age 5 and again at age 7 years. Z-scores were calculated using U.S. growth references for weight (WTZ), height (HTZ), and weight-for-length or BMI-for-age (WLZ/BMIZ). Mid-upper arm circumference (MUACZ) and triceps skinfold thickness (TSFZ) Z-scores were obtained from ages 1 and 2, respectively, through age 7 years. Piecewise mixed-effects models, overall and stratified by race and sex, were fit to assess differential growth patterns across age by maternal PHIV status. Results: One thousand four hundred fifty-four singleton infants (286 CHEU-PHIV and 1168 CHEU-NPHIV) were included. CHEU-PHIV had slower growth rates than CHEU-NPHIV for WTZ and WLZ/BMIZ at earlier ages and continued to have lower mean WTZ [-0.27, 95% confidence interval (95% CI): -0.50, -0.04] and WLZ/BMIZ (-0.39, 95% CI: -0.67, -0.11) through age 7. Among non-Black boys, CHEU-PHIV had slightly lower WTZ and WLZ/BMIZ at birth than CHEU-NPHIV and these growth deficits persisted through age 7 years. Conclusion: Compared with CHEU-NPHIV, CHEU-PHIV had diminished growth in early childhood with differences most pronounced among non-Black male children. Further longitudinal follow-up of CHEU-PHIV into young adulthood is needed to understand whether these early effects of maternal PHIV status on growth persist and have other health consequences.
KW - Child development
KW - HIV-exposed uninfected infants
KW - Maternal
KW - Perinatal HIV infection
KW - Postnatal growth
UR - http://www.scopus.com/inward/record.url?scp=85125212583&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125212583&partnerID=8YFLogxK
U2 - 10.1097/QAD.0000000000003136
DO - 10.1097/QAD.0000000000003136
M3 - Article
C2 - 34860195
AN - SCOPUS:85125212583
VL - 36
SP - 593
EP - 603
JO - AIDS
JF - AIDS
SN - 0269-9370
IS - 4
ER -